Search results
Results from the WOW.Com Content Network
Aminoglycoside antibiotics display bactericidal activity against Gram-negative aerobes and some anaerobic bacilli where resistance has not yet arisen but generally not against Gram-positive and anaerobic Gram-negative bacteria. [3] Streptomycin is the first-in-class aminoglycoside antibiotic.
Pages in category "Aminoglycoside antibiotics" The following 34 pages are in this category, out of 34 total. This list may not reflect recent changes. ...
The following is a list of antibiotics. The highest division between antibiotics is bactericidal and bacteriostatic . Bactericidals kill bacteria directly, whereas bacteriostatics prevent them from dividing.
Streptomycin is an antibiotic medication used to treat a number of bacterial infections, [3] including tuberculosis, Mycobacterium avium complex, endocarditis, brucellosis, Burkholderia infection, plague, tularemia, and rat bite fever. [3] For active tuberculosis it is often given together with isoniazid, rifampicin, and pyrazinamide. [4]
The antibiotics chloramphenicol, clindamycin, and tetracycline have been known to inactivate aminoglycosides in general by pharmacological antagonism. [ 9 ] The effect of amikacin is increased when used with drugs derived from the botulinum toxin , [ 17 ] anesthetics , neuromuscular blocking agents, or large doses of blood that contains citrate ...
Other natural products, this time primary metabolites rather than secondary metabolites, have been shown to eradicate antibiotic tolerance. For example, glucose, mannitol, and fructose reduce antibiotic tolerance in Escherichia coli and Staphylococcus aureus, rendering them more susceptible to killing by aminoglycoside antibiotics. [191]
Using antibiotics is linked to disturbance of the gut microbiome, which may have effects on cognitive function. However, a new study may help reassure older adults who are concerned about taking ...
The ESBLs are frequently plasmid encoded. Plasmids responsible for ESBL production frequently carry genes encoding resistance to other drug classes (for example, aminoglycosides). Therefore, antibiotic options in the treatment of ESBL-producing organisms are extremely limited.